| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 37 | 2025 | 2147 | 4.250 |
Why?
|
| Acute Coronary Syndrome | 8 | 2022 | 267 | 1.760 |
Why?
|
| Immunosuppressive Agents | 11 | 2024 | 858 | 1.690 |
Why?
|
| American Heart Association | 11 | 2024 | 300 | 1.650 |
Why?
|
| Cardiovascular Agents | 7 | 2018 | 157 | 1.550 |
Why?
|
| Health Resources | 4 | 2016 | 115 | 1.430 |
Why?
|
| Atrial Fibrillation | 16 | 2021 | 376 | 1.420 |
Why?
|
| Medical Marijuana | 4 | 2024 | 111 | 1.410 |
Why?
|
| Heart Transplantation | 14 | 2025 | 722 | 1.310 |
Why?
|
| Stroke Volume | 8 | 2023 | 592 | 1.150 |
Why?
|
| Anti-Arrhythmia Agents | 13 | 2014 | 112 | 1.110 |
Why?
|
| Marijuana Smoking | 2 | 2021 | 247 | 1.090 |
Why?
|
| Polypharmacy | 5 | 2023 | 84 | 1.070 |
Why?
|
| Drug Interactions | 14 | 2021 | 397 | 1.010 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2019 | 321 | 1.000 |
Why?
|
| Defibrillators, Implantable | 11 | 2001 | 300 | 0.980 |
Why?
|
| Health Expenditures | 3 | 2025 | 180 | 0.980 |
Why?
|
| Drug Overdose | 2 | 2022 | 325 | 0.950 |
Why?
|
| Electric Countershock | 9 | 2001 | 105 | 0.950 |
Why?
|
| Graft Rejection | 6 | 2025 | 598 | 0.930 |
Why?
|
| Humans | 170 | 2025 | 129687 | 0.920 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2022 | 253 | 0.910 |
Why?
|
| Opioid-Related Disorders | 3 | 2024 | 483 | 0.900 |
Why?
|
| Propanolamines | 3 | 2019 | 97 | 0.880 |
Why?
|
| Cost of Illness | 3 | 2014 | 277 | 0.850 |
Why?
|
| Aminobutyrates | 1 | 2023 | 33 | 0.810 |
Why?
|
| Cocaine | 2 | 2019 | 150 | 0.800 |
Why?
|
| Theophylline | 1 | 2022 | 68 | 0.780 |
Why?
|
| Remote Consultation | 1 | 2022 | 46 | 0.770 |
Why?
|
| Drugs, Generic | 2 | 2020 | 21 | 0.770 |
Why?
|
| Arrhythmias, Cardiac | 9 | 2001 | 321 | 0.760 |
Why?
|
| Consensus | 3 | 2024 | 617 | 0.760 |
Why?
|
| Cardiovascular Diseases | 9 | 2025 | 2008 | 0.750 |
Why?
|
| Health Care Costs | 2 | 2014 | 367 | 0.710 |
Why?
|
| Organ Transplantation | 2 | 2021 | 228 | 0.710 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 430 | 0.670 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2017 | 15 | 0.670 |
Why?
|
| Drug Hypersensitivity | 5 | 2008 | 81 | 0.670 |
Why?
|
| Hospitalization | 13 | 2024 | 2075 | 0.660 |
Why?
|
| Aged | 56 | 2022 | 22101 | 0.640 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2011 | 168 | 0.620 |
Why?
|
| Inpatients | 2 | 2016 | 477 | 0.610 |
Why?
|
| Cardiovascular System | 1 | 2020 | 136 | 0.610 |
Why?
|
| Anti-Infective Agents | 5 | 2010 | 248 | 0.610 |
Why?
|
| Middle Aged | 64 | 2025 | 31165 | 0.590 |
Why?
|
| Male | 90 | 2025 | 63691 | 0.590 |
Why?
|
| Practice Guidelines as Topic | 5 | 2025 | 1506 | 0.580 |
Why?
|
| Prescription Drugs | 2 | 2016 | 112 | 0.580 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 233 | 0.580 |
Why?
|
| United States | 26 | 2025 | 13906 | 0.580 |
Why?
|
| Lung Transplantation | 1 | 2020 | 290 | 0.560 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2024 | 1271 | 0.560 |
Why?
|
| Heart Rate | 16 | 2021 | 803 | 0.550 |
Why?
|
| Tachycardia, Ventricular | 10 | 2001 | 168 | 0.540 |
Why?
|
| Sick Leave | 2 | 2014 | 11 | 0.540 |
Why?
|
| Female | 85 | 2025 | 68751 | 0.530 |
Why?
|
| Purines | 2 | 2022 | 172 | 0.530 |
Why?
|
| Pregnancy Complications, Cardiovascular | 4 | 2001 | 78 | 0.530 |
Why?
|
| Drug Monitoring | 5 | 2016 | 215 | 0.520 |
Why?
|
| Chronic Disease | 8 | 2020 | 1723 | 0.520 |
Why?
|
| Anticoagulants | 8 | 2021 | 637 | 0.520 |
Why?
|
| Treatment Outcome | 18 | 2025 | 10221 | 0.510 |
Why?
|
| Drug Costs | 3 | 2025 | 100 | 0.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 2443 | 0.510 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 36 | 0.500 |
Why?
|
| Ranolazine | 1 | 2015 | 25 | 0.490 |
Why?
|
| Public Health | 1 | 2020 | 487 | 0.490 |
Why?
|
| Pharmacists | 5 | 2025 | 247 | 0.490 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 89 | 0.490 |
Why?
|
| Survival | 1 | 2015 | 38 | 0.490 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 82 | 0.480 |
Why?
|
| Angina, Stable | 1 | 2015 | 17 | 0.480 |
Why?
|
| Prescription Drug Misuse | 1 | 2015 | 39 | 0.480 |
Why?
|
| Hospital Costs | 1 | 2016 | 115 | 0.470 |
Why?
|
| Cardiac Pacing, Artificial | 9 | 2001 | 86 | 0.460 |
Why?
|
| Calcium Channel Blockers | 2 | 2015 | 161 | 0.460 |
Why?
|
| Employer Health Costs | 1 | 2014 | 3 | 0.460 |
Why?
|
| Physical Therapy Specialty | 2 | 2006 | 50 | 0.460 |
Why?
|
| Cardiology | 4 | 2024 | 266 | 0.460 |
Why?
|
| Pyrazoles | 2 | 2022 | 403 | 0.460 |
Why?
|
| Mortality | 2 | 2015 | 308 | 0.450 |
Why?
|
| Patient Discharge | 6 | 2021 | 856 | 0.450 |
Why?
|
| Adult | 45 | 2025 | 35607 | 0.450 |
Why?
|
| Vasodilator Agents | 5 | 2016 | 326 | 0.450 |
Why?
|
| Patient Admission | 1 | 2016 | 183 | 0.450 |
Why?
|
| Electrocardiography | 18 | 2013 | 611 | 0.440 |
Why?
|
| Drug Utilization Review | 2 | 2006 | 57 | 0.440 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2023 | 198 | 0.430 |
Why?
|
| Aged, 80 and over | 17 | 2021 | 7064 | 0.430 |
Why?
|
| Retrospective Studies | 21 | 2025 | 14525 | 0.430 |
Why?
|
| Tacrolimus | 4 | 2016 | 193 | 0.430 |
Why?
|
| Muscular Diseases | 2 | 2019 | 108 | 0.420 |
Why?
|
| Pain | 3 | 2022 | 786 | 0.410 |
Why?
|
| Catheter Ablation | 6 | 2000 | 336 | 0.410 |
Why?
|
| Hospital Mortality | 2 | 2016 | 851 | 0.410 |
Why?
|
| Daptomycin | 1 | 2013 | 19 | 0.410 |
Why?
|
| Creatine Kinase | 1 | 2013 | 75 | 0.410 |
Why?
|
| Drug Prescriptions | 3 | 2010 | 248 | 0.400 |
Why?
|
| Sulfonamides | 5 | 2013 | 497 | 0.400 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 133 | 0.390 |
Why?
|
| Pharmaceutical Services | 1 | 2013 | 81 | 0.390 |
Why?
|
| Baroreflex | 5 | 2021 | 53 | 0.390 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2018 | 443 | 0.380 |
Why?
|
| Models, Organizational | 1 | 2013 | 145 | 0.380 |
Why?
|
| Hiccup | 1 | 2011 | 3 | 0.380 |
Why?
|
| Dietary Supplements | 4 | 2016 | 532 | 0.380 |
Why?
|
| Pharmacy Service, Hospital | 4 | 2015 | 90 | 0.380 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 22 | 0.370 |
Why?
|
| Ventricular Fibrillation | 4 | 2001 | 57 | 0.370 |
Why?
|
| Amines | 1 | 2011 | 37 | 0.370 |
Why?
|
| Cities | 1 | 2012 | 105 | 0.370 |
Why?
|
| Medicaid | 1 | 2015 | 433 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2018 | 1282 | 0.360 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 5 | 2000 | 30 | 0.360 |
Why?
|
| Atrioventricular Node | 4 | 1997 | 15 | 0.360 |
Why?
|
| Medication Errors | 3 | 2013 | 96 | 0.350 |
Why?
|
| Patient Education as Topic | 3 | 2013 | 743 | 0.350 |
Why?
|
| Drug Substitution | 3 | 2020 | 51 | 0.350 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 1021 | 0.340 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 287 | 0.340 |
Why?
|
| Risk Factors | 13 | 2025 | 9787 | 0.340 |
Why?
|
| Adenosine | 3 | 2018 | 227 | 0.340 |
Why?
|
| Transplant Recipients | 3 | 2017 | 163 | 0.330 |
Why?
|
| Aircraft | 3 | 2001 | 22 | 0.330 |
Why?
|
| Colorado | 9 | 2022 | 4405 | 0.330 |
Why?
|
| Heart Conduction System | 9 | 2001 | 95 | 0.330 |
Why?
|
| Central Nervous System Agents | 1 | 2009 | 5 | 0.330 |
Why?
|
| Electrocardiography, Ambulatory | 6 | 1999 | 58 | 0.330 |
Why?
|
| Seizures | 2 | 2012 | 401 | 0.330 |
Why?
|
| Desensitization, Immunologic | 2 | 2008 | 90 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2024 | 2014 | 0.320 |
Why?
|
| Clinical Protocols | 3 | 2017 | 254 | 0.320 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 231 | 0.310 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 69 | 0.310 |
Why?
|
| Electrodes, Implanted | 4 | 1997 | 105 | 0.310 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 903 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2020 | 385 | 0.300 |
Why?
|
| Premature Birth | 1 | 2012 | 317 | 0.290 |
Why?
|
| Cost Sharing | 1 | 2008 | 14 | 0.290 |
Why?
|
| Citalopram | 1 | 2008 | 30 | 0.290 |
Why?
|
| Restless Legs Syndrome | 1 | 2008 | 21 | 0.290 |
Why?
|
| Helicobacter Infections | 1 | 2007 | 29 | 0.280 |
Why?
|
| Pacemaker, Artificial | 3 | 2001 | 110 | 0.280 |
Why?
|
| Ticlopidine | 1 | 2008 | 54 | 0.280 |
Why?
|
| Helicobacter pylori | 1 | 2007 | 38 | 0.280 |
Why?
|
| Exanthema | 1 | 2008 | 74 | 0.270 |
Why?
|
| Zygomycosis | 1 | 2007 | 6 | 0.270 |
Why?
|
| Tachycardia, Supraventricular | 6 | 2001 | 44 | 0.270 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2018 | 22 | 0.270 |
Why?
|
| Managed Care Programs | 1 | 2008 | 132 | 0.270 |
Why?
|
| Imidazolidines | 3 | 2001 | 10 | 0.270 |
Why?
|
| Carbazoles | 2 | 2011 | 84 | 0.270 |
Why?
|
| Analgesics | 1 | 2008 | 190 | 0.270 |
Why?
|
| Cyclosporine | 3 | 2010 | 263 | 0.260 |
Why?
|
| Epistaxis | 1 | 2006 | 13 | 0.260 |
Why?
|
| Telemedicine | 1 | 2015 | 792 | 0.260 |
Why?
|
| Warfarin | 4 | 2021 | 147 | 0.260 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2006 | 74 | 0.260 |
Why?
|
| Health Behavior | 1 | 2012 | 743 | 0.260 |
Why?
|
| Comorbidity | 6 | 2016 | 1551 | 0.250 |
Why?
|
| Salvage Therapy | 1 | 2007 | 136 | 0.250 |
Why?
|
| Fructose | 1 | 2006 | 108 | 0.250 |
Why?
|
| Sympathetic Nervous System | 5 | 2001 | 174 | 0.250 |
Why?
|
| Triazoles | 1 | 2007 | 148 | 0.240 |
Why?
|
| Imidazoles | 3 | 2001 | 235 | 0.240 |
Why?
|
| Diabetic Neuropathies | 1 | 2006 | 96 | 0.240 |
Why?
|
| Metronidazole | 1 | 2005 | 20 | 0.240 |
Why?
|
| Models, Economic | 2 | 2016 | 53 | 0.240 |
Why?
|
| Tobacco, Smokeless | 1 | 2024 | 10 | 0.240 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2025 | 567 | 0.230 |
Why?
|
| Ventricular Function, Left | 4 | 2023 | 528 | 0.230 |
Why?
|
| Medication Adherence | 5 | 2018 | 561 | 0.230 |
Why?
|
| Time Factors | 12 | 2016 | 6545 | 0.230 |
Why?
|
| Smoking | 1 | 2012 | 1502 | 0.230 |
Why?
|
| Coronary Disease | 2 | 1998 | 385 | 0.230 |
Why?
|
| Risk Assessment | 7 | 2022 | 3260 | 0.220 |
Why?
|
| Mood Disorders | 2 | 2016 | 121 | 0.220 |
Why?
|
| Thrombosis | 2 | 2021 | 349 | 0.220 |
Why?
|
| Nitrous Oxide | 1 | 2024 | 31 | 0.220 |
Why?
|
| Cytomegalovirus | 1 | 2025 | 154 | 0.220 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2025 | 130 | 0.220 |
Why?
|
| Piperazines | 3 | 2001 | 339 | 0.220 |
Why?
|
| Young Adult | 8 | 2024 | 12457 | 0.220 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2005 | 121 | 0.220 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2014 | 56 | 0.220 |
Why?
|
| Prognosis | 7 | 2025 | 3772 | 0.220 |
Why?
|
| Methadone | 1 | 2024 | 91 | 0.210 |
Why?
|
| Length of Stay | 3 | 2016 | 1127 | 0.210 |
Why?
|
| Cardiac Catheterization | 4 | 2008 | 520 | 0.210 |
Why?
|
| Research Design | 1 | 2009 | 1045 | 0.210 |
Why?
|
| Metoprolol | 3 | 2001 | 39 | 0.210 |
Why?
|
| Adolescent | 11 | 2024 | 20415 | 0.210 |
Why?
|
| Vagus Nerve | 2 | 1996 | 86 | 0.210 |
Why?
|
| Nurse Clinicians | 1 | 2024 | 43 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 1 | 2025 | 189 | 0.210 |
Why?
|
| Opiate Substitution Treatment | 1 | 2024 | 136 | 0.200 |
Why?
|
| Valsartan | 1 | 2023 | 27 | 0.200 |
Why?
|
| Pressoreceptors | 2 | 2021 | 19 | 0.200 |
Why?
|
| Postoperative Complications | 3 | 2025 | 2470 | 0.200 |
Why?
|
| Aminophylline | 1 | 2022 | 10 | 0.200 |
Why?
|
| Biphenyl Compounds | 1 | 2023 | 60 | 0.200 |
Why?
|
| Patient Transfer | 1 | 2024 | 163 | 0.200 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 137 | 0.200 |
Why?
|
| Sodium | 1 | 2023 | 205 | 0.190 |
Why?
|
| Nitroprusside | 3 | 2016 | 67 | 0.190 |
Why?
|
| Nicotine | 1 | 2024 | 303 | 0.190 |
Why?
|
| Drug Therapy, Combination | 6 | 2016 | 1042 | 0.190 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 1022 | 0.190 |
Why?
|
| Education, Pharmacy | 3 | 2016 | 119 | 0.190 |
Why?
|
| Fluorobenzenes | 2 | 2013 | 15 | 0.190 |
Why?
|
| Heart-Assist Devices | 2 | 2021 | 537 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 2 | 2020 | 61 | 0.190 |
Why?
|
| Folic Acid | 4 | 2016 | 182 | 0.190 |
Why?
|
| Drug Combinations | 1 | 2023 | 331 | 0.190 |
Why?
|
| Troponin I | 2 | 2000 | 75 | 0.190 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 913 | 0.190 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2001 | 33 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 1368 | 0.180 |
Why?
|
| Hyperthermia, Induced | 8 | 2000 | 108 | 0.180 |
Why?
|
| Administration, Oral | 6 | 2024 | 787 | 0.180 |
Why?
|
| Cognition Disorders | 2 | 2016 | 505 | 0.180 |
Why?
|
| Buprenorphine | 1 | 2024 | 162 | 0.180 |
Why?
|
| Equipment Failure | 6 | 2001 | 106 | 0.180 |
Why?
|
| Students, Pharmacy | 2 | 2016 | 96 | 0.180 |
Why?
|
| Azithromycin | 1 | 2001 | 93 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 1708 | 0.180 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 302 | 0.170 |
Why?
|
| Policy Making | 1 | 2021 | 88 | 0.170 |
Why?
|
| Kidney Failure, Chronic | 2 | 2005 | 546 | 0.170 |
Why?
|
| Follow-Up Studies | 9 | 2025 | 4892 | 0.170 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 1103 | 0.170 |
Why?
|
| Tachycardia, Paroxysmal | 3 | 1995 | 7 | 0.170 |
Why?
|
| Equipment Design | 6 | 2001 | 514 | 0.160 |
Why?
|
| Heart Arrest | 3 | 2001 | 320 | 0.160 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 263 | 0.160 |
Why?
|
| Reflex, Abnormal | 1 | 1999 | 7 | 0.160 |
Why?
|
| Skilled Nursing Facilities | 1 | 2021 | 131 | 0.160 |
Why?
|
| Drugs, Chinese Herbal | 1 | 1999 | 15 | 0.160 |
Why?
|
| Alzheimer Disease | 2 | 2016 | 516 | 0.160 |
Why?
|
| Canada | 1 | 2020 | 353 | 0.160 |
Why?
|
| Prospective Studies | 8 | 2020 | 7145 | 0.160 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 205 | 0.160 |
Why?
|
| Health Personnel | 1 | 2005 | 656 | 0.160 |
Why?
|
| Blood Pressure | 6 | 2021 | 1736 | 0.160 |
Why?
|
| Coated Materials, Biocompatible | 1 | 1999 | 59 | 0.150 |
Why?
|
| Cannabinoids | 1 | 2021 | 154 | 0.150 |
Why?
|
| Cardiologists | 1 | 2018 | 46 | 0.150 |
Why?
|
| Heart Injuries | 1 | 1999 | 36 | 0.150 |
Why?
|
| Exercise Test | 3 | 2021 | 614 | 0.150 |
Why?
|
| Glucose | 2 | 2023 | 1003 | 0.150 |
Why?
|
| Benzazepines | 1 | 2018 | 39 | 0.150 |
Why?
|
| Monitoring, Ambulatory | 1 | 1999 | 83 | 0.150 |
Why?
|
| Pyrimidines | 2 | 2013 | 458 | 0.150 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1998 | 54 | 0.140 |
Why?
|
| Triazines | 1 | 1998 | 38 | 0.140 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 1998 | 38 | 0.140 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 66 | 0.140 |
Why?
|
| Health Policy | 3 | 2024 | 354 | 0.140 |
Why?
|
| Food, Fortified | 1 | 1997 | 37 | 0.130 |
Why?
|
| Dexamethasone | 1 | 1999 | 352 | 0.130 |
Why?
|
| Diuretics | 1 | 2017 | 76 | 0.130 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1997 | 53 | 0.130 |
Why?
|
| Patient Participation | 1 | 2020 | 414 | 0.130 |
Why?
|
| Clinical Competence | 4 | 2012 | 1018 | 0.130 |
Why?
|
| Mexiletine | 1 | 2016 | 6 | 0.130 |
Why?
|
| Thiocyanates | 1 | 2016 | 31 | 0.130 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 46 | 0.130 |
Why?
|
| Thiosulfates | 1 | 2016 | 19 | 0.130 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2006 | 38 | 0.130 |
Why?
|
| Mitoxantrone | 1 | 1996 | 14 | 0.130 |
Why?
|
| Tetralogy of Fallot | 1 | 1997 | 78 | 0.130 |
Why?
|
| Amphetamine | 1 | 2016 | 25 | 0.130 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 5427 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 227 | 0.130 |
Why?
|
| Neural Tube Defects | 1 | 1997 | 58 | 0.130 |
Why?
|
| Medication Reconciliation | 2 | 2013 | 29 | 0.130 |
Why?
|
| Ventricular Function | 1 | 1996 | 61 | 0.130 |
Why?
|
| Hemodynamics | 5 | 2021 | 1091 | 0.130 |
Why?
|
| Regression Analysis | 6 | 2016 | 997 | 0.130 |
Why?
|
| Professional Role | 3 | 2025 | 158 | 0.120 |
Why?
|
| Anticonvulsants | 1 | 1998 | 208 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 580 | 0.120 |
Why?
|
| Amiodarone | 3 | 2001 | 25 | 0.120 |
Why?
|
| Rosuvastatin Calcium | 2 | 2013 | 20 | 0.120 |
Why?
|
| Nonprescription Drugs | 1 | 2016 | 66 | 0.120 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2016 | 88 | 0.120 |
Why?
|
| Nitroglycerin | 1 | 2015 | 17 | 0.120 |
Why?
|
| Certification | 2 | 2006 | 95 | 0.120 |
Why?
|
| Patient Safety | 2 | 2016 | 289 | 0.120 |
Why?
|
| Sex Factors | 3 | 2015 | 1973 | 0.120 |
Why?
|
| Omeprazole | 2 | 2007 | 6 | 0.120 |
Why?
|
| Hypoglycemic Agents | 2 | 2005 | 1220 | 0.120 |
Why?
|
| Patient Readmission | 3 | 2021 | 668 | 0.120 |
Why?
|
| Societies, Pharmaceutical | 2 | 2013 | 21 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2017 | 231 | 0.120 |
Why?
|
| Substance Abuse Detection | 1 | 2016 | 79 | 0.120 |
Why?
|
| Intensive Care Units | 3 | 2019 | 737 | 0.120 |
Why?
|
| Pre-Excitation Syndromes | 1 | 1995 | 5 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 569 | 0.120 |
Why?
|
| Age Distribution | 1 | 2015 | 372 | 0.120 |
Why?
|
| Insurance, Disability | 1 | 2014 | 1 | 0.120 |
Why?
|
| Lymphoma | 1 | 1996 | 198 | 0.120 |
Why?
|
| Health Services | 1 | 2015 | 99 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2016 | 177 | 0.110 |
Why?
|
| Prevalence | 3 | 2023 | 2563 | 0.110 |
Why?
|
| Antidotes | 1 | 2016 | 136 | 0.110 |
Why?
|
| Fever | 1 | 1996 | 298 | 0.110 |
Why?
|
| Partial Thromboplastin Time | 1 | 2014 | 52 | 0.110 |
Why?
|
| Patient Care Team | 2 | 2025 | 601 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 243 | 0.110 |
Why?
|
| Risk | 2 | 2017 | 855 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 151 | 0.110 |
Why?
|
| Life Style | 2 | 2018 | 462 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2024 | 744 | 0.110 |
Why?
|
| Absenteeism | 1 | 2014 | 47 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2000 | 110 | 0.110 |
Why?
|
| Hemorrhage | 4 | 2021 | 679 | 0.110 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 64 | 0.110 |
Why?
|
| Efficiency | 1 | 2014 | 92 | 0.110 |
Why?
|
| Proton Pump Inhibitors | 2 | 2007 | 100 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2005 | 381 | 0.110 |
Why?
|
| Mass Casualty Incidents | 1 | 2014 | 36 | 0.110 |
Why?
|
| Quality Improvement | 3 | 2020 | 1108 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 201 | 0.110 |
Why?
|
| Disease Management | 3 | 2024 | 588 | 0.110 |
Why?
|
| Homicide | 1 | 2014 | 61 | 0.110 |
Why?
|
| Torsades de Pointes | 1 | 2013 | 22 | 0.110 |
Why?
|
| Linear Models | 1 | 2016 | 821 | 0.100 |
Why?
|
| Blood Pressure Determination | 1 | 2014 | 148 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2018 | 1269 | 0.100 |
Why?
|
| Procainamide | 1 | 1993 | 6 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2014 | 239 | 0.100 |
Why?
|
| Medicare | 2 | 2015 | 719 | 0.100 |
Why?
|
| Calcineurin Inhibitors | 2 | 2010 | 69 | 0.100 |
Why?
|
| Simvastatin | 1 | 2013 | 60 | 0.100 |
Why?
|
| Medical Staff | 1 | 2012 | 16 | 0.100 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 67 | 0.100 |
Why?
|
| Pancreatitis | 2 | 2005 | 129 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1500 | 0.100 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2012 | 9 | 0.100 |
Why?
|
| Dog Diseases | 4 | 1999 | 51 | 0.100 |
Why?
|
| Pregnancy | 5 | 2012 | 6412 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 122 | 0.100 |
Why?
|
| Models, Educational | 1 | 2012 | 91 | 0.090 |
Why?
|
| Phenylephrine | 3 | 1999 | 75 | 0.090 |
Why?
|
| Acute Disease | 3 | 2018 | 980 | 0.090 |
Why?
|
| Maternal Age | 1 | 2012 | 125 | 0.090 |
Why?
|
| Physicians | 1 | 2020 | 871 | 0.090 |
Why?
|
| Bisoprolol | 1 | 2011 | 4 | 0.090 |
Why?
|
| Critical Care | 2 | 2016 | 551 | 0.090 |
Why?
|
| Foundations | 1 | 2011 | 24 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2015 | 253 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3381 | 0.090 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2012 | 85 | 0.090 |
Why?
|
| Dogs | 10 | 2000 | 385 | 0.090 |
Why?
|
| Health Services Misuse | 2 | 2020 | 35 | 0.090 |
Why?
|
| Sinoatrial Node | 1 | 1991 | 27 | 0.090 |
Why?
|
| Residence Characteristics | 2 | 2012 | 332 | 0.090 |
Why?
|
| Prostatic Hyperplasia | 1 | 2011 | 41 | 0.090 |
Why?
|
| Research Report | 1 | 2011 | 76 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2016 | 5434 | 0.090 |
Why?
|
| Wounds, Gunshot | 1 | 2014 | 213 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 515 | 0.090 |
Why?
|
| Drug Information Services | 2 | 2013 | 10 | 0.090 |
Why?
|
| Contraindications | 2 | 2002 | 90 | 0.090 |
Why?
|
| Primary Prevention | 2 | 2010 | 190 | 0.090 |
Why?
|
| Piperidines | 1 | 1992 | 200 | 0.080 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 467 | 0.080 |
Why?
|
| Heart Atria | 3 | 2000 | 129 | 0.080 |
Why?
|
| DNA | 1 | 2016 | 1406 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 318 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 522 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2012 | 367 | 0.080 |
Why?
|
| Complementary Therapies | 1 | 2010 | 87 | 0.080 |
Why?
|
| Pregabalin | 1 | 2008 | 8 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2062 | 0.080 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2008 | 15 | 0.080 |
Why?
|
| Monoamine Oxidase | 1 | 2008 | 27 | 0.070 |
Why?
|
| Antiparkinson Agents | 1 | 2008 | 28 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2009 | 226 | 0.070 |
Why?
|
| Pharmacogenetics | 2 | 2020 | 172 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 401 | 0.070 |
Why?
|
| Biological Products | 1 | 2011 | 207 | 0.070 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2008 | 23 | 0.070 |
Why?
|
| Cardiomyopathies | 3 | 2017 | 340 | 0.070 |
Why?
|
| Benchmarking | 2 | 2023 | 176 | 0.070 |
Why?
|
| Age Factors | 3 | 2009 | 3153 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 827 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2009 | 123 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2015 | 1875 | 0.070 |
Why?
|
| Ofloxacin | 1 | 2007 | 24 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2010 | 240 | 0.070 |
Why?
|
| Levofloxacin | 1 | 2007 | 25 | 0.070 |
Why?
|
| Cardiotonic Agents | 2 | 1999 | 126 | 0.070 |
Why?
|
| Peer Review, Research | 1 | 2008 | 41 | 0.070 |
Why?
|
| Drug-Eluting Stents | 1 | 2008 | 74 | 0.070 |
Why?
|
| Amoxicillin | 1 | 2007 | 30 | 0.070 |
Why?
|
| Combined Modality Therapy | 6 | 2000 | 1201 | 0.070 |
Why?
|
| Injections, Intravenous | 2 | 2001 | 202 | 0.070 |
Why?
|
| Atrial Function | 2 | 1999 | 11 | 0.070 |
Why?
|
| Mucor | 1 | 2007 | 7 | 0.070 |
Why?
|
| Vitamin B 12 | 3 | 2016 | 121 | 0.070 |
Why?
|
| Accreditation | 1 | 2007 | 80 | 0.070 |
Why?
|
| Hydantoins | 3 | 2001 | 4 | 0.070 |
Why?
|
| Hydrochlorothiazide | 1 | 2006 | 9 | 0.070 |
Why?
|
| Atrial Flutter | 3 | 2000 | 35 | 0.070 |
Why?
|
| Community Pharmacy Services | 1 | 2007 | 43 | 0.070 |
Why?
|
| Hypertension | 2 | 2014 | 1242 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 5083 | 0.070 |
Why?
|
| Neuralgia | 1 | 2008 | 128 | 0.070 |
Why?
|
| Angioedema | 1 | 2006 | 16 | 0.070 |
Why?
|
| Registries | 1 | 2014 | 1896 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 2 | 2005 | 117 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2010 | 1005 | 0.060 |
Why?
|
| Antidepressive Agents | 2 | 2005 | 229 | 0.060 |
Why?
|
| Professional Autonomy | 1 | 2006 | 29 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2006 | 171 | 0.060 |
Why?
|
| Ovarian Neoplasms | 3 | 2005 | 482 | 0.060 |
Why?
|
| Preceptorship | 1 | 2006 | 63 | 0.060 |
Why?
|
| Creatinine | 2 | 2005 | 490 | 0.060 |
Why?
|
| Education, Continuing | 1 | 2006 | 40 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 171 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2006 | 485 | 0.060 |
Why?
|
| Hospitals, University | 1 | 2006 | 180 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2006 | 118 | 0.060 |
Why?
|
| alpha-Tocopherol | 2 | 2016 | 33 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 764 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 646 | 0.060 |
Why?
|
| Curriculum | 2 | 2016 | 925 | 0.060 |
Why?
|
| Norepinephrine | 3 | 2021 | 209 | 0.060 |
Why?
|
| New South Wales | 1 | 2024 | 14 | 0.060 |
Why?
|
| Biotransformation | 1 | 2005 | 67 | 0.060 |
Why?
|
| Oxidoreductases | 1 | 2005 | 92 | 0.060 |
Why?
|
| Incidence | 3 | 2023 | 2644 | 0.060 |
Why?
|
| Sarcoma | 3 | 2000 | 175 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 1000 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2005 | 151 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2006 | 1021 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2006 | 263 | 0.050 |
Why?
|
| Biological Transport | 1 | 2005 | 405 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2000 | 506 | 0.050 |
Why?
|
| Ovary | 1 | 2005 | 209 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 402 | 0.050 |
Why?
|
| Reflex | 2 | 1996 | 65 | 0.050 |
Why?
|
| Educational Status | 1 | 2006 | 473 | 0.050 |
Why?
|
| Peroneal Nerve | 2 | 2001 | 19 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 399 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2006 | 709 | 0.050 |
Why?
|
| Decision Making | 2 | 2019 | 863 | 0.050 |
Why?
|
| HIV Infections | 1 | 2017 | 2730 | 0.050 |
Why?
|
| Myocardial Ischemia | 2 | 2001 | 259 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2008 | 462 | 0.050 |
Why?
|
| Health Status | 1 | 2008 | 758 | 0.050 |
Why?
|
| Cimetidine | 1 | 2002 | 13 | 0.050 |
Why?
|
| Paget Disease, Extramammary | 1 | 2002 | 4 | 0.050 |
Why?
|
| Recurrence | 3 | 2001 | 1012 | 0.050 |
Why?
|
| Graft Survival | 1 | 2025 | 514 | 0.050 |
Why?
|
| Facial Neoplasms | 1 | 2002 | 18 | 0.050 |
Why?
|
| Mass Screening | 1 | 2010 | 1192 | 0.050 |
Why?
|
| Patient Selection | 1 | 2006 | 660 | 0.050 |
Why?
|
| Histamine H2 Antagonists | 1 | 2002 | 29 | 0.050 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2002 | 78 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2002 | 80 | 0.050 |
Why?
|
| Depression | 2 | 2008 | 1322 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 680 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 713 | 0.050 |
Why?
|
| Electrophysiology | 3 | 2000 | 213 | 0.040 |
Why?
|
| Valsalva Maneuver | 1 | 2021 | 8 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 302 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2001 | 1270 | 0.040 |
Why?
|
| Axilla | 1 | 2001 | 45 | 0.040 |
Why?
|
| Sodium Channel Blockers | 1 | 2001 | 24 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2000 | 299 | 0.040 |
Why?
|
| Potassium Channel Blockers | 1 | 2001 | 36 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 2000 | 21 | 0.040 |
Why?
|
| Orbital Neoplasms | 1 | 2000 | 21 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2000 | 48 | 0.040 |
Why?
|
| Action Potentials | 3 | 2000 | 485 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2012 | 5759 | 0.040 |
Why?
|
| Volunteers | 1 | 2000 | 29 | 0.040 |
Why?
|
| Bundle of His | 1 | 2000 | 17 | 0.040 |
Why?
|
| Retreatment | 1 | 2000 | 70 | 0.040 |
Why?
|
| Shoulder | 1 | 2001 | 86 | 0.040 |
Why?
|
| Bundle-Branch Block | 1 | 2000 | 30 | 0.040 |
Why?
|
| Parasympathectomy | 1 | 2000 | 1 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2006 | 735 | 0.040 |
Why?
|
| Survival Rate | 2 | 2004 | 1872 | 0.040 |
Why?
|
| Sarcoma, Experimental | 1 | 2000 | 7 | 0.040 |
Why?
|
| United States Food and Drug Administration | 2 | 2001 | 205 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 237 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2021 | 112 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1204 | 0.040 |
Why?
|
| Tilt-Table Test | 1 | 1999 | 8 | 0.040 |
Why?
|
| Maximum Allowable Concentration | 1 | 1999 | 14 | 0.040 |
Why?
|
| Angelica sinensis | 1 | 1999 | 2 | 0.040 |
Why?
|
| Weight Loss | 1 | 2005 | 740 | 0.040 |
Why?
|
| Prothrombin Time | 1 | 1999 | 33 | 0.040 |
Why?
|
| Thoracotomy | 2 | 1997 | 74 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 1999 | 46 | 0.040 |
Why?
|
| Transitional Care | 1 | 2019 | 38 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2019 | 46 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 1999 | 23 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 1327 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2025 | 718 | 0.040 |
Why?
|
| Data Display | 1 | 1999 | 20 | 0.040 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1999 | 12 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2000 | 219 | 0.040 |
Why?
|
| Telephone | 3 | 1995 | 168 | 0.040 |
Why?
|
| Cisplatin | 2 | 1993 | 299 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 1999 | 53 | 0.040 |
Why?
|
| Rhabdomyolysis | 1 | 2019 | 22 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2006 | 1235 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2000 | 1433 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2005 | 670 | 0.040 |
Why?
|
| Delirium | 1 | 2019 | 76 | 0.040 |
Why?
|
| Heart Diseases | 2 | 2005 | 352 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1999 | 370 | 0.040 |
Why?
|
| Resuscitation | 1 | 2000 | 237 | 0.040 |
Why?
|
| Heart Failure, Systolic | 1 | 2018 | 25 | 0.040 |
Why?
|
| Echocardiography | 2 | 1998 | 635 | 0.040 |
Why?
|
| Hydrogen | 1 | 1998 | 65 | 0.040 |
Why?
|
| Heart Ventricles | 2 | 2000 | 781 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2019 | 105 | 0.040 |
Why?
|
| Child | 3 | 2015 | 20882 | 0.040 |
Why?
|
| Cannabis | 1 | 2024 | 462 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1999 | 162 | 0.040 |
Why?
|
| Heart Block | 1 | 1997 | 40 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2000 | 231 | 0.040 |
Why?
|
| Animals | 12 | 2010 | 35404 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 3084 | 0.030 |
Why?
|
| Digoxin | 1 | 1997 | 28 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 1994 | 541 | 0.030 |
Why?
|
| Bread | 1 | 1997 | 4 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1994 | 176 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2010 | 4935 | 0.030 |
Why?
|
| Edible Grain | 1 | 1997 | 48 | 0.030 |
Why?
|
| Body Surface Area | 1 | 1997 | 33 | 0.030 |
Why?
|
| Frailty | 1 | 2019 | 152 | 0.030 |
Why?
|
| Energy Intake | 1 | 2019 | 462 | 0.030 |
Why?
|
| Anesthetics | 1 | 2017 | 66 | 0.030 |
Why?
|
| Nutritional Requirements | 1 | 1997 | 77 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 265 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 1998 | 673 | 0.030 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 5 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2016 | 32 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 1996 | 53 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1997 | 269 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 1996 | 94 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 542 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2017 | 150 | 0.030 |
Why?
|
| Surface Properties | 1 | 1997 | 399 | 0.030 |
Why?
|
| Neutropenia | 1 | 1996 | 137 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 421 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 133 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 1003 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 361 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 385 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 336 | 0.030 |
Why?
|
| Factor X | 1 | 2014 | 25 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 154 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 1996 | 189 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 541 | 0.030 |
Why?
|
| PubMed | 1 | 2013 | 10 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 1994 | 67 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 534 | 0.030 |
Why?
|
| Medical Assistance | 1 | 2013 | 10 | 0.030 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2013 | 17 | 0.030 |
Why?
|
| Acecainide | 1 | 1993 | 1 | 0.030 |
Why?
|
| Disaster Planning | 1 | 2014 | 83 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1994 | 317 | 0.030 |
Why?
|
| Heparin | 1 | 2014 | 254 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2013 | 81 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 529 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1993 | 109 | 0.020 |
Why?
|
| Antibodies | 1 | 2014 | 399 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 1995 | 282 | 0.020 |
Why?
|
| Stroke | 1 | 2021 | 1072 | 0.020 |
Why?
|
| Program Development | 1 | 2014 | 355 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 72 | 0.020 |
Why?
|
| Education | 1 | 2012 | 104 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2016 | 877 | 0.020 |
Why?
|
| Biological Availability | 1 | 1992 | 147 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2011 | 30 | 0.020 |
Why?
|
| Internationality | 1 | 2012 | 149 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2012 | 185 | 0.020 |
Why?
|
| Urinary Retention | 1 | 2011 | 20 | 0.020 |
Why?
|
| Random Allocation | 1 | 1992 | 347 | 0.020 |
Why?
|
| Kidney | 1 | 2019 | 1383 | 0.020 |
Why?
|
| Self Care | 1 | 2014 | 368 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2012 | 293 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 1829 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 1016 | 0.020 |
Why?
|
| Body Temperature | 1 | 1992 | 212 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 171 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1995 | 391 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1999 | 1149 | 0.020 |
Why?
|
| Critical Illness | 1 | 2016 | 759 | 0.020 |
Why?
|
| Neutrophils | 1 | 1996 | 1209 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1839 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 527 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 91 | 0.020 |
Why?
|
| Reference Values | 1 | 1991 | 796 | 0.020 |
Why?
|
| Terminal Care | 1 | 2012 | 216 | 0.020 |
Why?
|
| Micronutrients | 1 | 2010 | 88 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2009 | 27 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2724 | 0.020 |
Why?
|
| Heart | 2 | 1995 | 645 | 0.020 |
Why?
|
| Biomarkers | 2 | 2016 | 3969 | 0.020 |
Why?
|
| Journal Impact Factor | 1 | 2009 | 28 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 636 | 0.020 |
Why?
|
| Food | 1 | 2010 | 156 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 2628 | 0.020 |
Why?
|
| Tricuspid Valve | 1 | 1987 | 27 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2012 | 609 | 0.020 |
Why?
|
| Caregivers | 1 | 2015 | 807 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 836 | 0.020 |
Why?
|
| Internship, Nonmedical | 1 | 2006 | 14 | 0.020 |
Why?
|
| Specialty Boards | 1 | 2006 | 32 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2006 | 133 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2510 | 0.020 |
Why?
|
| Schools, Pharmacy | 1 | 2006 | 46 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 304 | 0.020 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2005 | 2 | 0.020 |
Why?
|
| Faculty | 1 | 2006 | 138 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2000 | 541 | 0.020 |
Why?
|
| Temperature | 3 | 1999 | 635 | 0.020 |
Why?
|
| Furosemide | 1 | 2005 | 39 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 45 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2006 | 483 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1994 | 3394 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 84 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2004 | 23 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1996 | 2044 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 42 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 195 | 0.010 |
Why?
|
| Azathioprine | 1 | 2004 | 50 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2005 | 306 | 0.010 |
Why?
|
| Gout | 1 | 2005 | 33 | 0.010 |
Why?
|
| Everolimus | 1 | 2004 | 88 | 0.010 |
Why?
|
| Diphosphonates | 1 | 2005 | 58 | 0.010 |
Why?
|
| Hypolipidemic Agents | 1 | 2005 | 92 | 0.010 |
Why?
|
| Mycophenolic Acid | 1 | 2004 | 110 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 126 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 380 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1993 | 2102 | 0.010 |
Why?
|
| Infection Control | 1 | 2005 | 141 | 0.010 |
Why?
|
| Myocardial Contraction | 2 | 1999 | 335 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 341 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 756 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 1917 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1616 | 0.010 |
Why?
|
| Sirolimus | 1 | 2004 | 270 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2005 | 228 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 311 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2004 | 318 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 1204 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 836 | 0.010 |
Why?
|
| Cheek | 1 | 2002 | 15 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2005 | 328 | 0.010 |
Why?
|
| Methylmalonic Acid | 1 | 2002 | 63 | 0.010 |
Why?
|
| Mohs Surgery | 1 | 2002 | 25 | 0.010 |
Why?
|
| Legislation, Medical | 1 | 2001 | 11 | 0.010 |
Why?
|
| Device Approval | 1 | 2001 | 21 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2004 | 398 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2005 | 231 | 0.010 |
Why?
|
| Homocysteine | 1 | 2002 | 152 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 532 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1690 | 0.010 |
Why?
|
| Partial Pressure | 1 | 2000 | 30 | 0.010 |
Why?
|
| Parasympathetic Nervous System | 1 | 2000 | 27 | 0.010 |
Why?
|
| Central Venous Pressure | 1 | 1999 | 14 | 0.010 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 1999 | 14 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 2002 | 232 | 0.010 |
Why?
|
| Epinephrine | 1 | 2000 | 141 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2000 | 328 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1999 | 251 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1999 | 92 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2000 | 296 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2004 | 886 | 0.010 |
Why?
|
| Biopsy | 1 | 2002 | 1087 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 229 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 406 | 0.010 |
Why?
|
| Cutaneous Fistula | 1 | 1995 | 13 | 0.010 |
Why?
|
| Oxygen | 1 | 2000 | 916 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 1995 | 100 | 0.010 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 7 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1993 | 38 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1993 | 31 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1993 | 27 | 0.010 |
Why?
|
| Half-Life | 1 | 1993 | 162 | 0.010 |
Why?
|
| Microelectrodes | 1 | 1993 | 43 | 0.010 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1993 | 19 | 0.010 |
Why?
|
| Extracellular Space | 1 | 1993 | 120 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 266 | 0.010 |
Why?
|
| Phosphates | 1 | 1994 | 181 | 0.010 |
Why?
|
| Survivors | 1 | 1996 | 462 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1992 | 65 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1995 | 1199 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1993 | 463 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1994 | 481 | 0.010 |
Why?
|
| Hepatitis, Animal | 1 | 1987 | 2 | 0.000 |
Why?
|
| Endocardium | 1 | 1987 | 33 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1987 | 112 | 0.000 |
Why?
|
| Tachycardia | 1 | 1987 | 57 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1987 | 171 | 0.000 |
Why?
|
| Peritonitis | 1 | 1987 | 81 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1987 | 316 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1987 | 1090 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1987 | 471 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1987 | 385 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1994 | 10487 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1987 | 4076 | 0.000 |
Why?
|